New Jersey Clinical Trials Report — April 2026

For New Jersey residents considering participation in clinical research, April 2026 brings a critical reminder: time is running out for many opportunities. A total of 102 clinical trials across the state are scheduled to close their enrollment within the next 90 days. This includes 14 trials that are actively seeking healthy volunteers, offering a chance to contribute to medical science without needing a specific health condition. If you've been thinking about joining a study, now is the moment to explore these options before they are no longer available.

Patients managing specific health challenges also have a limited window to enroll in studies focused on their conditions. Trials nearing their close date cover a range of important health areas, including various cancers, cardiovascular issues, and mental health. Conditions with trials closing soon include:

• Breast cancer
• Atrial fibrillation
• Ovarian cancer
• Sarcoma
• Stroke
• Ovarian carcinoma
• Colon cancer
• Major depressive disorder
• Non-small cell lung cancer

Major Advancements: New Trials Launching in New Jersey

This month, New Jersey welcomes 15 new clinical trials, adding to the state's robust research landscape. While this number is lower than the 28 trials that opened in March 2026, the new studies include significant Phase 2 and 3 investigations from prominent sponsors, offering participants access to cutting-edge medical research.

Among the most notable new trials are several large-scale studies addressing critical health concerns:

• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, a Phase 3 study investigating the use of methylprednisolone in people undergoing liver surgery. This trial aims to enroll 750 participants to determine if the medication can reduce post-surgical side effects like infections and shorten hospital stays.
• Incyte Corporation is launching NCT07522073, a Phase 3 study evaluating a new combination therapy for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants to assess the efficacy and safety of standard chemotherapy with or without INCB161734.
• Novartis Pharmaceuticals is initiating NCT07512063, a study focused on real-world treatment patterns and outcomes for HR+/HER2- metastatic breast cancer patients receiving first-line CDK4/6 inhibitors. This study plans to involve 480 participants.
• Praxis Precision Medicines is sponsoring NCT07505004, a Phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures. This study is designed for 300 participants.
• Memorial Sloan Kettering Cancer Center is also leading NCT07516925, a Phase 2 study to assess the effectiveness and safety of Ivonescimab for people with advanced or unresectable leiomyosarcoma, involving 20 participants.

Exploring New Conditions and Geographic Reach

The 15 new trials opened this month are investigating a diverse array of conditions, reflecting the breadth of medical research underway in New Jersey. These include studies focused on:

• Non-small cell lung cancer
• Carotenoid status
• Complete edentulism
• Coronary artery disease (CAD)
• Coronary calcification
• Coronary calcified disease
• Coronary calcified nodules
• Diffuse pleural mesothelioma
• Focal epilepsy
• Food insecurity

The majority of these new opportunities are drug trials, accounting for 9 of the new studies, followed by device trials and other types of research. Academic institutions and industry sponsors are both contributing significantly to this new wave of research. Memorial Sloan Kettering Cancer Center leads with 5 new trials, while Rutgers, The State University of New Jersey is sponsoring 2. Other notable sponsors include Novartis Pharmaceuticals, Praxis Precision Medicines, Ultragenyx Pharmaceutical Inc, and AstraZeneca.

Geographically, new trials are opening in several key areas across New Jersey, making participation accessible to residents in various regions. Cities with the highest number of new trials this month include:

• Basking Ridge (4 new trials)
• Middletown (4 new trials)
• Montvale (4 new trials)
• Newark (2 new trials)
• Hackensack (2 new trials)

Additional trials have opened in Marlboro, Raritan, Teaneck, Morristown, and Neptune City. Overall, New Jersey boasts an impressive 1,635 clinical trials currently recruiting across 165 cities and 1,071 research sites, demonstrating widespread accessibility for those interested in participating.

Who Can Participate? Opportunities for Healthy Volunteers and Diverse Demographics

Clinical trials in New Jersey are designed to include a wide range of participants. Of the 15 new trials launched this month, 13 are open to older adults, ensuring that senior populations have ample opportunities to contribute to medical advancements. Additionally, one new trial is specifically for female participants, and another is for male participants. While no new trials this month are recruiting children, the overall landscape of research in the state often includes pediatric studies.

For individuals who do not have a specific health condition, there are valuable opportunities to contribute as healthy volunteers. 2 of the new trials this month are actively seeking healthy participants. Looking statewide, a total of 130 clinical trials are currently recruiting healthy volunteers, providing numerous avenues for those interested in supporting medical research and helping to establish baseline data for new treatments.

As we move through April, the focus remains on the ongoing enrollment in these vital studies, particularly those with impending deadlines. New Jersey continues to be a hub for medical innovation, and the coming months are expected to bring further opportunities for residents to play a direct role in shaping the future of healthcare.